

Electronic Acknowledgement Receipt

EFS ID:	8851098
Application Number:	10550331
International Application Number:	
Confirmation Number:	2103
Title of Invention:	SYNERGY OF DOPAMINE D2 AND ADENOSINE A2 RECEPTORS ACTIVATES PKA SIGNALING VIA BETA/GAMMA DIMERS
First Named Inventor/Applicant Name:	Adrienne S. Gordon
Customer Number:	00758
Filer:	Pauline Farmer-Koppenol
Filer Authorized By:	
Attorney Docket Number:	27432-16428
Receipt Date:	16-NOV-2010
Filing Date:	22-FEB-2007
Time Stamp:	20:09:43
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	GOLDSMITH_Dopamine.pdf	1594931 0e2dbc7bbac8d525d6daca96e7dd705d506722a	no	24

Warnings:

Information:

2	NPL Documents	GORDON_Ethanol_Alters.pdf	593304	no	6
			0a9f9f2ecf7261aeb4ee04233a5fef24f2de156d		
Warnings:					
Information:					
3	NPL Documents	GORDON_Phosphorylation.pdf	720671	no	9
			03fce9a9cac895c4ef7321da5d44674aa41a0cd		
Warnings:					
Information:					
4	NPL Documents	GREEN_Dopaminergic.pdf	812368	no	9
			612b6a0d17723abc3f17d72cb9bea9c02661d5de		
Warnings:					
Information:					
5	NPL Documents	HAMM.pdf	607599	no	4
			637873c25736e872420fd45806f04fcedff78fa6		
Warnings:					
Information:					
6	NPL Documents	HANDA_Cloning.pdf	670663	no	7
			cc6baae2a00384350ae88892ad33bb1a48cb2d28		
Warnings:					
Information:					
7	NPL Documents	HASIN_Difficulties.pdf	575665	no	7
			e17a0239cee1f23c0b2d1841b5c0d15c888478d3		
Warnings:					
Information:					
8	NPL Documents	HEBERLEIN_Star.pdf	1507516	no	15
			8a81ef34905852ae77ce5ef4117ce4c8a18f3309		
Warnings:					
Information:					
9	NPL Documents	HODGE_The_Discriminative.pdf	339141	no	13
			111829e3f9ffa2a007e9dc9d15001d9a24ce9d2d		
Warnings:					
Information:					
10	NPL Documents	HONKANEN_Alcohol.pdf	585059	no	7
			43c8a1a047426a732b54aec8fbfaff9c5638bc8e		
Warnings:					
Information:					

11	NPL Documents	HUNDLE_An_E_PKC.pdf	130100	no	2
			2e80607083bd89971f8c7aaee6dcb72c4773ab21		
Warnings:					
Information:					
12	NPL Documents	HUNDLE_An_Inhibitory.pdf	1002233	no	8
			931e9eebf1d803778168009604bbe9e61f3630eb		
Warnings:					
Information:					
13	NPL Documents	HUNDLE_Overexpression.pdf	655170	no	7
			c4e61763533536b7af00e476b390be0e5acd2d43		
Warnings:					
Information:					
14	NPL Documents	INGLESE.pdf	565411	no	5
			f3a976128a403ac1b58378c34227845a4c3e64a0		
Warnings:					
Information:					
15	NPL Documents	ISRAEL_Acetate.pdf	502123	no	5
			ed2d64a464643b8e6385e999d8bf92090e79634a		
Warnings:					
Information:					
16	NPL Documents	JACOBSON_8.pdf	342820	no	4
			6bd5717225448834aaca791ab34aee28a213b93c		
Warnings:					
Information:					
17	NPL Documents	JARVIS_Direct.pdf	330275	no	4
			8803cb1e55ab84adee58f02471f5bd2c327b4065		
Warnings:					
Information:					
18	NPL Documents	JARVIS_Single.pdf	813487	no	9
			bd797b279d62adb926cd76af6c32eb6ef87272e3		
Warnings:					
Information:					
19	NPL Documents	KAPLAN_Adenosine.pdf	818688	no	7
			ebe96b125e72ace8b1b63b06dbe11f0242d5e3b		
Warnings:					
Information:					

20	NPL Documents	KAPLAN_Role.pdf	520474	no	6
			0d785cf1d9d4657260314934716285ff443e5249		
Warnings:					
Information:					
21	NPL Documents	KITSON_Drugs.pdf	294590	no	3
			1bcb8b8fbf980d85a7fae32450a7fa505d2018121		
Warnings:					
Information:					
22	NPL Documents	KOCH_Cellular.pdf	414005	no	5
			6ddd3691d5a5cbc7a2f5d66ab51889fac8f24ff3		
Warnings:					
Information:					
23	NPL Documents	KOOB_Neural.pdf	907463	no	31
			bb4402062d40f3a32dd8d579961261e5a85d6ffa		
Warnings:					
Information:					
24	NPL Documents	KRAUSS_Inhibition.pdf	611817	no	6
			cfc80d8675555c26fe08875f518493b70de802ac		
Warnings:					
Information:					
25	NPL Documents	LANE-LADD_CREB.pdf	935630	no	12
			4c6304f753cb396b79db6a9d9023b0189c18b613		
Warnings:					
Information:					
26	NPL Documents	LEDENT_Aggressiveness.pdf	642025	no	5
			4ce32bb44748d2e5ddb5386870fd9a18a12a9e6a		
Warnings:					
Information:					
27	NPL Documents	MALEC_Influence.pdf	370143	no	6
			576c1b9f315646031d42bcbd60582fe250750b09		
Warnings:					
Information:					
28	NPL Documents	MATHEW_Craving.pdf	710862	no	5
			ae6b57c5ecf0b1d16bf6347155a4e2d44375ae94		
Warnings:					
Information:					

29	NPL Documents	MESSING_Chronic_Ethanol.pdf	784166	no	5
			c9840fbc2a150f4e82d296a80038f801a59ec52f		
Warnings:					
Information:					
30	NPL Documents	MESSING_Protein.pdf	209002	no	9
			bc8b494d7d4215fbc6885f3d0f4c41d33fc5d1f8		
Warnings:					
Information:					
31	NPL Documents	MILES_Mechanism.pdf	432259	no	6
			25b3d006c2b07fcc93cb93d4c36a3622ace67469		
Warnings:					
Information:					
32	NPL Documents	MILES_Phosducin.pdf	427325	no	5
			6429d35bd2575d03b7ff4627b4a2b9457063a2a9		
Warnings:					
Information:					
33	NPL Documents	MISERENDINO_Behavioral.pdf	614350	no	8
			1207e2fe8a87a47f592eb023cf4f97b24659cd757		
Warnings:					
Information:					
34	NPL Documents	MOCHLY_Rosen_Anchoring.pdf	842401	no	9
			bf985040ea0abb9122e0e5d9f15b99af9a2cd429d		
Warnings:					
Information:					
35	NPL Documents	MOCHLY-ROSEN_Chronic.pdf	468715	no	3
			c01d3e6ab19a9f12cb7c44aa70302e47b019b93e		
Warnings:					
Information:					
36	NPL Documents	MOCHLY-ROSEN_Identification.pdf	368543	no	4
			d13e68c053912dfb4030293262d3b86c44a4926e4		
Warnings:					
Information:					
37	NPL Documents	MYERS_Irreversible.pdf	792858	no	9
			d933f288f83aa18ae7494ce4b4d1513dd7cd5a20c		
Warnings:					
Information:					

38	NPL Documents	MYERS_Suppression.pdf	834240	no	11
			0da2707c94e244ecc272f548de03f408af7d66d3		
Warnings:					
Information:					
39	NPL Documents	NAASSILA_Low.pdf	799656	no	7
			5dce7405d1dde364cbe97001bbf99db24270a697		
Warnings:					
Information:					
40	NPL Documents	NAGY_cAMP.pdf	215493	no	8
			6ea032daabc1c234bd31d8e083f375ddaba6600		
Warnings:					
Information:					
41	NPL Documents	NESTLER_Molecular.pdf	877639	no	6
			87aec3b0854c0f12adc704c8a3b9504cd7defc43		
Warnings:					
Information:					
42	NPL Documents	NIBUYA_Chronic.pdf	818685	no	8
			ffa9092d2aafb2fb1f664ca921abfe949bb12467e		
Warnings:					
Information:					
43	NPL Documents	NIKODIJEVIC_Behavioral.pdf	975536	no	9
			dbdfb350ca5fc465bd9f39cf122336b180c2573a		
Warnings:					
Information:					
44	NPL Documents	OKANE_Interaction.pdf	342099	no	11
			26e540c406c8a69e9cbc24a0fac4997afb54ff75f		
Warnings:					
Information:					
45	NPL Documents	ONGINI_Selective.pdf	322818	no	4
			e42f1241c76fc1ec747a3f6e3856a4fe96added6		
Warnings:					
Information:					
46	NPL Documents	ORREGO_Ethanol.pdf	749053	no	7
			ecbecaea41872a081f4f01386c167e0058d8df27		
Warnings:					
Information:					

47	NPL Documents	ORREGO_New_Insights.pdf	619019	no	11
			2e03ecf4fb5b0d56438a91ac7c1ec6411cbb1732		
Warnings:					
Information:					
48	NPL Documents	ORTIZ_Biochemical.pdf	920776	no	10
			2e6284ade9d015823999668f40d1427960ed061f		
Warnings:					
Information:					
49	NPL Documents	ORTIZ_Exracellular.pdf	702201	no	13
			d1ec6955423fd66573fdb5d7ebe9765b3e0cbffe		
Warnings:					
Information:					
50	NPL Documents	PCT_US2005-20992_SR_WO_2007-04-20.pdf	220973	no	6
			6920ce23c104e9c433714b1912c4a9b80e0278ad		
Warnings:					
Information:					
51	NPL Documents	PIOMELLI_Dopamine.pdf	416866	no	6
			0bf9f3b5f4b189b597498bdc6d9e96873be6ff28		
Warnings:					
Information:					
52	NPL Documents	POLICH_Epi.pdf	752545	no	8
			d06399b6f7e95ea338460230c5d47f0e6c25a508		
Warnings:					
Information:					
53	NPL Documents	ROIVAINEN_Ethanol.pdf	559677	no	5
			857705675ada1eac1f255bebc5ba1f4fd9bee42		
Warnings:					
Information:					
54	NPL Documents	ROIVAINEN_Protein_Kinase_C_Adaptation.pdf	155086	no	12
			5cc31a6a0b1dc9f5da5542caa98d8599296a391b		
Warnings:					
Information:					
55	NPL Documents	ROIVAINEN_Protein_Kinase_C_Isozymes.pdf	725783	no	11
			9f5380373819f2d740092709ca0eb30d79935c61		
Warnings:					
Information:					

56	NPL Documents	ROIVAINEN_The_Phorbol.pdf	222583 d9c54e2911ddb89d800445ab19a5a360acd9e909	no	4
Warnings:					
Information:					
57	NPL Documents	RON_Agonists.pdf	466921 868dcb5330f0ab6bcb5acae624ba5d034b25ab89	no	4
Warnings:					
Information:					
58	NPL Documents	RON_Autoregulatory.pdf	528618 6f806bbbfbe40654b8fa1542002aa5be39dd04f	no	5
Warnings:					
Information:					
59	NPL Documents	RON_C2_Region.pdf	965042 06829c3d47a27bd12e6415e82daf96f60778c124	no	8
Warnings:					
Information:					
60	NPL Documents	RON_Cloning.pdf	577125 11b261d277b51688b07ccba7d8abfd56313d5a6	no	5
Warnings:					
Information:					
Total Files Size (in bytes):			37282286		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.